{"name":"Rapport Therapeutics","slug":"rapport-therapeutics","ticker":"RAPP","exchange":"NASDAQ","domain":"rapporttx.com","description":"Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.","hq":"Cambridge, MA","founded":0,"employees":"84","ceo":"Kristina Bhatt Patterson","sector":"Neuroscience / Epilepsy","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":38.19,"stockChange":0.11,"stockChangePercent":0.29,"marketCap":"$1.8B","metrics":{"revenue":20000000,"revenueGrowth":0,"grossMargin":34.3,"rdSpend":94789000,"netIncome":-111483000,"cash":52645000,"dividendYield":0,"peRatio":-8.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"RTX-1301 patent cliff ($1.2B at risk)","drug":"RTX-1301","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"RAP-219","genericName":"RAP-219","slug":"rap-219","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"RAP-219","genericName":"RAP-219","slug":"rap-219","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Rapport Therapeutics Announces FDA Fast Track Designation for RTX-1301","summary":"Rapport Therapeutics received FDA Fast Track designation for its lead asset, RTX-1301, for the treatment of epilepsy.","drugName":"RTX-1301","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Rapport Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Rapport Therapeutics reported its third quarter 2023 financial results, with a net loss of $23.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"trial","source":"simplywall.st","summary":"A Look At Rapport Therapeutics (RAPP) Valuation As RAP-219 Advances Toward Phase 2a Data And Phase 3 Plans - simplywall.st","headline":"A Look At Rapport Therapeutics (RAPP) Valuation As RAP-219 Advances Toward Phase 2a Data And Phase 3 Plans","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-03","type":"pipeline","source":"simplywall.st","summary":"Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform? - simplywall.st","headline":"Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNUWFkZ1pXZ2I1QmNVWmlJR2xaMFRZcUJKbzVrTVZUekVDeFhnZUpWVURXcFBfYW10SFJiMk1neTUzWllzd0J3Y1BUWjNiVUh5UEpfLWd1cks4ODI4Q1dhMG1MRGlfS0pzMVQtemo1dTFFVUJSaEVoRklzQUlaVmU3c2VIMW1pMzBkeE5xN2hJUkJvZG9MR2pEY0hKQmNhaGU5eFJsMFpTSWhpLWw3NFRoZUxlQXN2ZjliQXQxS09TWG9fWE9jeHpxdmhNM0VMalFPQ2E0NDlQNnhUeVQwd3dJQWN6WQ?oc=5","date":"2026-03-30","type":"pipeline","source":"Sahm","summary":"Assessing Rapport Therapeutics (RAPP) Valuation After Zacks Rank Upgrade And Strong One Year Return - Sahm","headline":"Assessing Rapport Therapeutics (RAPP) Valuation After Zacks Rank Upgrade And Strong One Year Return","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOZWZ3YXVBeWJvU1pmaXoxQ0ZtM1JUX0FTN2pYbnFJVENLb0ZHck5TelFWT21XSTBLQ1JlN2l0Qk9zbktOaHpDa0JWakdxX1hJY2dlbWVIRFNXSDJsbDdQSHJNa2g2UGFuWklRTHlocW5FYkZFU3RERzlTSk9IZTlGNnhBZ1NFb1h2cXVfV1F3Z3I5UVpTQzhPOERsQlYxczJOeThuODBxaGNiUm5Wd0Q2Z3NCRU85cW5CdDlOVHZtdld1UG1xbDFqQjZ2cjMtcVFCb055RU9B?oc=5","date":"2026-03-10","type":"pipeline","source":"Investing.com","summary":"Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential - Investing.com","headline":"Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQUmpQNHVRdzZzVGx4cW4wZW9Ca1lmWFlpYkN0Ul9SNERRYktqNWZzaUhZdlZtVnNOZ016c081TUZ2MTVhNmRJR3E1cFJldi1qLWc5QWwwN2cwejY2YW5Yd2xUZmtJbnlWbnZQa05JSXM3TDVYTTRVN3I1TDI0RWtrNTRQY3JILTRLTzhkWjNzcWw?oc=5","date":"2025-12-06","type":"pipeline","source":"Yahoo Finance","summary":"Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge - Yahoo Finance","headline":"Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOY3o0XzNHdjh6ZFdNTlJRS0diZFZMVll6TzRkbTlvRzMyc3oxUk1meFZzSVR6Zy1WSnBBbEkzYnQ3T19HRkR5QU1xb3hvZWJYS1FsTkk5MGZTSzRvOWVGaXIyNm95N2wzUVRUY0p1bUFlV0hCZ0d1Q1RnRk5DSGo3aVRuZ0REdkR0ME5za05OQUU0MnM5ZlpmZGln?oc=5","date":"2025-09-09","type":"trial","source":"The Pharma Letter","summary":"Rapport rockets on positive trial data for RAP219 - The Pharma Letter","headline":"Rapport rockets on positive trial data for RAP219","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNbmw2aTJBZDlsQnA4MmpYTXJpZ0tteFhPb3pleEhvWWRjaGFPQ0JZbHNvcHdwenE5c1oyY3lhNkVhV19oSzdaTlNyYXFtcVR1YWV3dnJiYXZiMkdFTHJBTFFraFdzblZVUWFtODRjbTFZRDE1Z1U5bWpqSUx2MXlncjdRY2oxaG1SSU5EN2pwMVBzMFZ3THVnQg?oc=5","date":"2025-09-08","type":"trial","source":"BioPharma Dive","summary":"Rapport shares double on better-than-expected seizure drug data - BioPharma Dive","headline":"Rapport shares double on better-than-expected seizure drug data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOZG56MTU4a1JuQm40RXZ1bnZSQmVvSmQxbnBhaG5qN2tZSVRnODZmd0pzWnYzT1FfaW1ybFZoa0R4UEFZR3lQeWN6RUpMd2pNLXFremMtQ3JxYjV6WE80VUJjQ25GUzZiS2h4eHVnRkJ6SU5OU3VKeGd6ZjZFZGdaRGQ3MU81UDRWbExMRF9BS3NCUFNQWjlLay13?oc=5","date":"2025-09-08","type":"trial","source":"Fierce Biotech","summary":"Rapport's seizure drug hits in phase 2, sending stock soaring - Fierce Biotech","headline":"Rapport's seizure drug hits in phase 2, sending stock soaring","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBaT0pSUWtSVnBVS2NKcEYyQmpwcjRaUUQtMmEwNFJYQkt2ZFdhQ0hlMlc4a2lOUWpuaEh3UFBnSXZDcmVQX1pVeHEzUy1oM1BxTW1V?oc=5","date":"2025-09-08","type":"pipeline","source":"firstwordpharma.com","summary":"KOL Views Preview: How does Rapport's RAP-219 stack up in a changing epilepsy landscape? - firstwordpharma.com","headline":"KOL Views Preview: How does Rapport's RAP-219 stack up in a changing epilepsy landscape?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNb0Q5ZmtCSUt2UFptQXJ6U2s5SXctb2VLNTc0UXlyTmlYRklSTUxXakc1MWY0MDBwb2NlTnpncnlMb0E0SjN6SlNJaTdnN0Q0VDg0WUNHY0ltcFBnZkFNaURRVklHcnltQmNScmtVUVhsYXZHYU5PVWlzTVhMTjdnTm1oLWpqVWdHbWlxMg?oc=5","date":"2025-09-08","type":"regulatory","source":"Tokenist","summary":"Why Did Rapport Therapeutics, Inc Shares Skyrocket in Premarket? - Tokenist","headline":"Why Did Rapport Therapeutics, Inc Shares Skyrocket in Premarket?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQMlE3MWJ1NDliR01zUmU1V0xndzc4a2J0VUN1bGlkWU9jZzNnYnpzSmcyVG9zZTFISmZmUjJvRXJzT1FFclEzZ1VGT1N1Vk1qTTdlc092U25BUGF1bjRmcnZ3TEd2V0FacGl0WWt6blJoVHNLekhDem1zdGl4Rzc1R2RZOVc4eXJzMlkwNFF5VWZMbjFYNWR6VU9vMlhoX3dEdWc?oc=5","date":"2025-09-08","type":"pipeline","source":"RagingBull","summary":"Rapport Therapeutics Stock Soars on Breakthrough Seizure Drug News - RagingBull","headline":"Rapport Therapeutics Stock Soars on Breakthrough Seizure Drug News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPbUVHQy16Y1dncXpyQXJJWEdZYnN1RXNkV1Vfam1CSkVmbkRIOWNWeFVqM3ZEb1dnTVh3YWpCSEYyYzVSU0pKc1cteXVDUl9mUmhzTXV5R1VBcXloV1dsc3d3dVJFb2FuM1JVVDhEMGVkR2x5SGVhNW1ScEY2OEtuME9Da0RieFR6TGRyNzF4UUNlLUd2cWE3QkdPRFVEalJSbzBWRVNzdXJfSzljcjhXVmw2dzV5TzJIeDZkcFp3?oc=5","date":"2025-09-05","type":"trial","source":"Stock Titan","summary":"Key Epilepsy Drug Trial Results Coming Monday: Rapport's RAP-219 Phase 2a Data Could Impact Treatment - Stock Titan","headline":"Key Epilepsy Drug Trial Results Coming Monday: Rapport's RAP-219 Phase 2a Data Could Impact Treatment","sentiment":"neutral"}],"patents":[{"drugName":"RTX-1301","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":["Ultragenyx Pharmaceutical","Zogenix","GW Pharmaceuticals"],"therapeuticFocus":["Neurology","Epilepsy"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":0},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":0}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":94789000,"rdSpendHistory":[{"period":"2025-12-31","value":94789000},{"period":"2024-12-31","value":60935000},{"period":"2023-12-31","value":27999000}],"sgaSpend":30310000,"operatingIncome":-125099000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-125099000},{"period":"2024-12-31","value":-83055000},{"period":"2023-12-31","value":-36179000}],"netIncome":-111483000,"netIncomeHistory":[{"period":"2025-12-31","value":-111483000},{"period":"2024-12-31","value":-78307000},{"period":"2023-12-31","value":-34786000}],"eps":-3.78,"epsHistory":[{"period":"2024-12-31","value":-3.78},{"period":"2023-12-31","value":-23.1}],"cash":52645000,"cashHistory":[{"period":"2025-12-31","value":52645000},{"period":"2024-12-31","value":56805000},{"period":"2023-12-31","value":70169000},{"period":"2022-12-31","value":31159000}],"totalAssets":512431000,"totalLiabilities":27778000,"totalDebt":11484000,"equity":484653000,"operatingCashflow":-87473000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-87473000},{"period":"2024-12-31","value":-64828000},{"period":"2023-12-31","value":-27181000}],"capex":-616000,"capexHistory":[{"period":"2025-12-31","value":-616000},{"period":"2024-12-31","value":-2405000},{"period":"2023-12-31","value":-1636000}],"freeCashflow":-88089000,"dividendsPaid":null,"buybacks":-1000,"employees":84,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":8251000,"ebit":-38509000,"ebitda":-38244000,"period":"2025-12-31","revenue":0,"epsBasic":-0.72,"netIncome":-33763000,"rdExpense":30258000,"epsDiluted":-0.72,"grossProfit":null,"operatingIncome":-38509000},{"sga":7707000,"ebit":-29986000,"ebitda":-29730000,"period":"2025-09-30","revenue":0,"epsBasic":-0.71,"netIncome":-26925000,"rdExpense":22279000,"epsDiluted":-0.71,"grossProfit":null,"operatingIncome":-29986000},{"sga":6816000,"ebit":-29496000,"ebitda":-29244000,"period":"2025-06-30","revenue":0,"epsBasic":-0.75,"netIncome":-26732000,"rdExpense":22680000,"epsDiluted":-0.75,"grossProfit":null,"operatingIncome":-29496000},{"sga":7536000,"ebit":-27108000,"ebitda":-26864000,"period":"2025-03-31","revenue":0,"epsBasic":-0.68,"netIncome":-24063000,"rdExpense":19572000,"epsDiluted":-0.68,"grossProfit":null,"operatingIncome":-27108000},{"sga":6322000,"ebit":-23521000,"ebitda":-23261000,"period":"2024-12-31","revenue":0,"epsBasic":-0.57,"netIncome":-19980000,"rdExpense":17199000,"epsDiluted":-0.57,"grossProfit":null,"operatingIncome":-23521000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":38.19,"previousClose":38.08,"fiftyTwoWeekHigh":42.27,"fiftyTwoWeekLow":7.73,"fiftyTwoWeekRange":"7.73 - 42.269","fiftyDayAverage":32.93,"twoHundredDayAverage":27.15,"beta":0,"enterpriseValue":1355270400,"forwardPE":-8.4,"priceToBook":3.87,"priceToSales":91.33,"enterpriseToRevenue":67.76,"enterpriseToEbitda":-11.18,"pegRatio":0,"ebitda":-121206000,"ebitdaMargin":0,"freeCashflow":-49431752,"operatingCashflow":-80297000,"totalDebt":10803000,"debtToEquity":2.3,"currentRatio":27.08,"returnOnAssets":-19.1,"returnOnEquity":-28.3,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":10,"targetMeanPrice":54.7,"targetHighPrice":80,"targetLowPrice":40,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.7,"institutionHeldPercent":107.4,"sharesOutstanding":47826929,"floatShares":31259203,"sharesShort":3048448,"shortRatio":8.86,"shortPercentOfFloat":6.4,"epsTrailing":-2.6,"epsForward":-4.54,"revenuePerShare":0.48,"bookValue":9.86,"officers":[{"age":74,"name":"Dr. Steven M. Paul M.D.","title":"Founder & Independent Chairman"},{"age":47,"name":"Mr. Abraham N. Ceesay M.B.A.","title":"CEO, President, Treasurer & Director"},{"age":57,"name":"Dr. Troy A. Ignelzi","title":"Chief Financial Officer"},{"age":55,"name":"Dr. Jeffrey  Sevigny M.D.","title":"Chief Medical Officer"},{"age":59,"name":"Dr. David  Bredt M.D., Ph.D.","title":"Founder & Chief Scientific Officer"},{"age":45,"name":"Ms. Cheryl  Gault","title":"Chief Operating Officer"},{"age":null,"name":"Ms. Karina  Chmielewski","title":"Chief Information Officer & Head of Operations"},{"age":null,"name":"Ms. Julie  DiCarlo","title":"Head of Communications & Investor Relations"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.rapportrx.com","phone":"857 321 8020"}}